Venous thrombosis

Indication for Reviparin

Population group: Suitable for both men and women, only adults (18 years old or older)

For this indication, competent medicine agencies globally authorize below treatments:

143 IU/kg in 2 divided doses daily

Route of admnistration


Defined daily dose

143 [iU] per kg of body weight

Dosage regimen

71.5 [iU] per kg of body weight 2 time(s) per day every day

Detailed description

A daily dose of 143 IU anti-Xa/kg body weight divided in two subcutaneous injections is recommended for the initial treatment of deep vein thrombosis). The maximum daily dose is 10,307 IU. Oral anticoagulation can be started at the same time with the goal of achieving a PK-INR (International Normalised Ratio) in the therapeutic target range of 2.0–3.0. Clivarin treatment should be given for at least 5-7 days.

In clinical studies the following dose scheme has proven to be effective:

Bodyweight Reviparin dose Volume
35-45 kg 2,863 IU anti-Xa twice daily 0.50 ml
46-60 kg 3,436 IU anti-Xa twice daily 0.60 ml
>60 kg 5,153 IU anti-Xa twice daily 0.90 ml

For patients over 60 kg experience is available with the administration of 10,307 IU once daily.

Active ingredient

Reviparin is a low molecular weight heparin and in clinical terms its action on blood coagulation is the most important biological effect. Reviparin is involved in different phases of blood coagulation. Because of its marked inhibitory action on factor Xa and comparatively low level of anti IIa activity, low molecular weight heparin is at its most active during the preliminary stages of coagulation.

Read more about Reviparin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner